RXR agonist S169 inhibits HBV/HDV entry in vitro by disrupting KIF4-dependent NTCP trafficking.
Sameh A. Gad, Doaa A Abo Elwafa, Saied A. Hussein, Kento Fukano, Takanobu Kato, Ikuo Shoji, Kazuaki Chayama, Masamichi Muramatsu, Masanori Isogawa, Takaji Wakita, Daniel Merk, Hussein Hassan Aly
This study identifies S169, an RXR agonist, as an inhibitor of HBV/HDV entry by disrupting KIF4-dependent NTCP trafficking in human hepatocytes.
Antiviral Research · Jun 14, 2025Peer-reviewedMicrobiology